Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

被引：121

作者：

Rotolo, Antonia ^{[1
]}

Caputo, Valentina S. ^{[1
]}

Holubova, Monika ^{[1
,2
]}

Baxan, Nicoleta ^{[3
]}

Dubois, Olivier ^{[3
]}

Chaudhry, Mohammed Suhail ^{[1
]}

Xiao, Xiaolin ^{[1
]}

Goudevenou, Katerina ^{[1
]}

Pitcher, David S. ^{[1
]}

Petevi, Kyriaki ^{[1
]}

Kachramanoglou, Carolina ^{[4
]}

Iles, Sandra ^{[5
]}

Naresh, Kikkeri ^{[1
]}

Maher, John ^{[6
]}

Karadimitris, Anastasios ^{[1
]}

机构：

[1] Imperial Coll London, Dept Med, Ctr Haematol, London, England

[2] Charles Univ Prague, Med Fac Pilsen, Biomed Ctr, Alej Svobody 76, Plzen 32300, Czech Republic

[3] Imperial Coll London, Dept Med, Biol Imaging Ctr, London, England

[4] Imperial Coll Healthcare NHS Trust, Dept Neuroradiol, London, England

[5] Hammersmith Hosp, Northwest London Pathol, Cellular Pathol, London, England

[6] Kings Coll London, Guys Hosp, Sch Canc & Pharmaceut Sci, London, England

来源：

CANCER CELL | 2018年 / 34卷 / 04期

关键词：

KILLER T-CELLS; INVARIANT NKT CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; VERSUS-HOST-DISEASE; B-CELLS; ADOPTIVE IMMUNOTHERAPY; ALPHA-GLYCOSYLCERAMIDE; DISTINCT SUBSETS; GENE-EXPRESSION; RECEPTOR;

D O I：

10.1016/j.ccell.2018.08.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19(+) B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19(+) chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.

引用

页码：596 / +

页数：26

共 50 条

[41] Augmentation of the anti-lymphoma activity of an anti-CD19 immunotoxin by anti-CD20 antibody is mediated via a complement-dependent mechanism.
Flavell, DJ
Warnes, SL
Symons, M
Noss, A
Flavell, SU
BLOOD, 2000, 96 (11) : 342A - 342A
[42] Pre-Clinical Evaluation of Allogeneic 'Off-the-Shelf' CAR-iNKT Cells Targeting CD19 (ALA-101)-Expressing Hematological Malignancies
Ponnusamy, Kanagaraju
Kanagaraju, Janani
Wang, Yingxin
Lye, Bryan
Ren, Hongwei
Armugam, Uthayamalar
Buchanan, Sandhya
Baker, Michael J.
Bharathan, Mini
Karadimitris, Anastasios
BLOOD, 2022, 140 : 12699 - 12700
[43] Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Ormhoj, Maria
Scarfo, Irene
Cabral, Maria L.
Bailey, Stefanie R.
Lorrey, Selena J.
Bouffard, Amanda A.
Castano, Ana P.
Larson, Rebecca C.
Riley, Lauren S.
Schmidts, Andrea
Choi, Bryan D.
Andersen, Rikke S.
Cedile, Oriane
Nyvold, Charlotte G.
Christensen, Jacob H.
Gjerstorff, Morten F.
Ditzel, Henrik J.
Weinstock, David M.
Barington, Torben
Frigault, Matthew J.
Maus, Marcela V.
CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7046 - 7057
[44] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Shaun Cordoba
Shimobi Onuoha
Simon Thomas
Daniela Soriano Pignataro
Rachael Hough
Sara Ghorashian
Ajay Vora
Denise Bonney
Paul Veys
Kanchan Rao
Giovanna Lucchini
Robert Chiesa
Jan Chu
Liz Clark
Mei Mei Fung
Koval Smith
Carlotta Peticone
Muhammad Al-Hajj
Vania Baldan
Mathieu Ferrari
Saket Srivastava
Ram Jha
Frederick Arce Vargas
Kevin Duffy
William Day
Paul Virgo
Lucy Wheeler
Jeremy Hancock
Farzin Farzaneh
Sabine Domning
Yiyun Zhang
Nushmia Z. Khokhar
Vijay G. R. Peddareddigari
Robert Wynn
Martin Pule
Persis J. Amrolia
Nature Medicine, 2021, 27 : 1797 - 1805
[45] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Cordoba, Shaun
Onuoha, Shimobi
Thomas, Simon
Pignataro, Daniela Soriano
Hough, Rachael
Ghorashian, Sara
Vora, Ajay
Bonney, Denise
Veys, Paul
Rao, Kanchan
Lucchini, Giovanna
Chiesa, Robert
Chu, Jan
Clark, Liz
Fung, Mei Mei
Smith, Koval
Peticone, Carlotta
Al-Hajj, Muhammad
Baldan, Vania
Ferrari, Mathieu
Srivastava, Saket
Jha, Ram
Vargas, Frederick Arce
Duffy, Kevin
Day, William
Virgo, Paul
Wheeler, Lucy
Hancock, Jeremy
Farzaneh, Farzin
Domning, Sabine
Zhang, Yiyun
Khokhar, Nushmia Z.
Peddareddigari, Vijay G. R.
Wynn, Robert
Pule, Martin
Amrolia, Persis J.
NATURE MEDICINE, 2021, 27 (10) : 1797 - +
[46] Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
Tong, Chuan
Zhang, Yajing
Liu, Yang
Ji, Xingyu
Zhang, Wenying
Guo, Yelei
Han, Xiao
Ti, Dongdong
Dai, Hanren
Wang, Chunmeng
Yang, Qingming
Liu, Wanli
Wang, Yao
Wu, Zhiqiang
Han, Weidong
BLOOD, 2020, 136 (14) : 1632 - 1644
[47] Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Denlinger, Nathan
Song, No-Joon
Zhang, Xiaoli
Jeon, Hyeongseon
Peterson, Chelsea
Wang, Yi
Reynolds, Kelsi
Bolz, Robert M.
Miao, Jessica
Song, Chunhua
Wu, Dayong
Chan, Wing Keung
Bezerra, Evandro
Epperla, Narendranath
Voorhees, Timothy J.
Brammer, Jonathan
Kittai, Adam S.
Bond, David A.
Sawalha, Yazeed
Sigmund, Audrey
Reneau, John C.
Rubinstein, Mark P.
Hanel, Walter
Christian, Beth
Baiocchi, Robert A.
Maddocks, Kami
Alinari, Lapo
Vasu, Sumithira
de Lima, Marcos
Chung, Dongjun
Jaglowski, Samantha
Li, Zihai
Huang, Xiaopei
Yang, Yiping
BLOOD ADVANCES, 2024, 8 (12) : 3140 - 3153
[48] Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/Refractory ALL Patients
Tang, Xiaowen
Kang, Liqing
Qi, Wei
Cui, Wei
Dai, Haiping
Li, Zheng
Yin, Jia
Qu, Changju
Xu, Ting
Zhu, Xiaming
Yu, Lei
Wu, Depei
BLOOD, 2019, 134
[49] Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia
Gu, Runxia
Liu, Fang
Zou, Dehui
Liu, Bingcheng
Liu, Wei
Chen, Xiaojuan
Liu, Kaiqi
Guo, Ye
Gong, Xiaoyuan
Lv, Rui
Chen, Xia
Zhou, Chunlin
Zhong, Mengjun
Xu, Yingxi
Wang, Huijun
Wei, Hui
Mi, Yingchang
Qiu, Lugui
Lv, Lulu
Wang, Min
Wang, Ying
Zhu, Xiaofan
Wang, Jianxiang
BLOOD, 2019, 134
[50] Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh
Melody Smith
Scott E James
Marco L Davila
Enrico Velardi
Kimon V Argyropoulos
Gertrude Gunset
Fabiana Perna
Fabiana M Kreines
Emily R Levy
Sophie Lieberman
Hillary V Jay
Andrea Z Tuckett
Johannes L Zakrzewski
Lisa Tan
Lauren F Young
Kate Takvorian
Jarrod A Dudakov
Robert R Jenq
Alan M Hanash
Ana Carolina F Motta
George F Murphy
Chen Liu
Andrea Schietinger
Michel Sadelain
Marcel R M van den Brink
Nature Medicine, 2017, 23 : 242 - 249

← 1 2 3 4 5 →